Clinical & Translational Radiation Oncology
@ctRO_journal
Followers
303
Following
115
Media
23
Statuses
63
👉 94 patients with isolated local relapse of prostate cancer after definitive irradiation. 👉 Salvage I-125 low-dose-rate brachytherapy was performed in a Comprehensive Cancer Center. 👉 Treatment of whole gland (70%) +- with an MRI-based GTV boost (20%) or focal (10%).
0
1
1
Compliance to MDT recs in OMD pts: 👉83.7% of MDT recommendations correctly implemented 👉Reasons for major deviations: physician decision, patient comorbidity or patient decision. 👉Major deviations associated with more than one distant met and worse OS https://t.co/z2D6i8hYWl
3
19
54
🎆 Now in @ctRO_journal Impact of Dose, fractionation and motion management on SBRT outcome in adrenal gland tumors. #radonc
1
1
5
Also don't miss the accompanying editorial by @cristian_udo @SahgalArjun @HaghighiNeda @drhsoli
https://t.co/LYh5uL8Kvv
#radonc
0
0
1
Should preoperative SRS be considered for brain metastases undergoing resection? Great to work with @HaghighiNeda @SahgalArjun @drhsoli on our @ctRO_journal editorial of the PREOP-1 trial. More prospective evidence for this novel paradigm! @Sunnybrook @UofTDRO @PeterMacRadOnc
1
16
45
🔹LDR Brachytherapy for recurrent prostate cancer after definitive radiotherapy https://t.co/476srxhZJI
#radonc
0
0
1
🦴 Study on Osteolytic Metastases (SM) Remineralization 🔬 Conclusion: Radiation therapy significantly increases BMD in lytic SM (except renal tumors). No additional benefit of SBRT over cEBRT. Important for surgical decisions in unstable patients. https://t.co/SNv7Yt1uXg
0
1
4
We are hiring!! We are looking for two associate editors for @ctro_journal! Apply now if you want to be part of a rapidly growing radiotherapy journal by @ESTRO_RT! https://t.co/eSRRQvNRc8
#radonc
0
2
7
Hot off the press in ctRO by Rogers et al. 🔷 Preoperative Radiosurgery is highly feasible when scheduled the day before neurosurgery. 🔷 The surgical cavity local control rate was equivalent to that reported with postoperative fractionated SRS https://t.co/2Jgyf9G5Rw
#radonc
1
4
8
And now... updated results of 41 patients CURATIVELY treated with 6m of Dostarlimab (PD-1) WITHOUT ☢️or🔪 ✅100% cCR rate ✅0 Local or distance relapses ✅Sustained cCR for > 12 m seen in 20 patients with mFU of 29 m THIS. IS. AWESOME #ASCO24
5
65
215
LAURA Trial receives a well deserved huge applause by the audience. Huge benefit in PFS (39 vs 5.6 mo, HR < 0.2. OS still immature and 81% crossover. STAGE III EGFR+ NSCLC INCURABLE? BRAIN RMN BUT NO PET-CT required at baseline. #ASCO24 @LeciaSequist
2
54
123
Your turn now to submit 👍 https://t.co/zZ8HZOiUBb
0
0
1